Clinical Trials Logo

Fear of Cancer Recurrence clinical trials

View clinical trials related to Fear of Cancer Recurrence.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04568226 Completed - Clinical trials for Fear of Cancer Recurrence

The Effect of Metacognition-based, Manualized Intervention on Fear of Cancer Recurrence

Start date: July 21, 2021
Phase: N/A
Study type: Interventional

The primary aim of this study is to assess the effect of ConquerFear, a metacognition-based manualized intervention on fear of cancer recurrence, using the randomized controlled trial approach, among Chinese patients newly diagnosed with curable cancer. This study aims to (1) test the direct effect of ConquerFear intervention on fear of cancer recurrence and on maladaptive metacognition, and (2) to test the indirect effect of ConquerFear intervention on fear of cancer recurrence through its effect on maladaptive metacognition.

NCT ID: NCT04535921 Completed - Prostate Cancer Clinical Trials

Fear of Cancer Recurrence in Genitourinary Cancer

Start date: November 5, 2019
Phase:
Study type: Observational

To perform an analysis of independent predictors of fear of cancer recurrence in patients with malignant genitourinary diseases and their impact on quality of life and survival

NCT ID: NCT04137575 Completed - Clinical trials for Breast Cancer Female

ConquerFear-Group: A Psychological Intervention for Fear of Cancer Recurrence

Start date: October 21, 2019
Phase: N/A
Study type: Interventional

The primary aim of this randomized controlled trial is to evaluate the effect of ConquerFear-Group (CF-G), compared with a control condition (CC), on Fear of Cancer Recurrence (FCR). Secondary aims are to explore the effect of CF-G on emotion regulation and additional psychological outcomes, and to explore mediating effects of emotion regulation, metacognitions, working alliance, patient adherence, and group cohesion. In addition, treatment expectancy, participation in other treatments after completion of the intervention of the study and demographic and clinical variables will be explored as moderators.